Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector28910.17816/psaic289ReviewsОбзорыUnknownAlpha-synuclein as a biomarker of Parkinson’s diseaseАльфа-синуклеин как биомаркер болезни ПаркинсонаPchelinaS. N.ПчелинаС. Н.
Russian Federation
sopchelina@hotmail.comSt. Petersburg State Medical University named after I.P. PavlovСанкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова1312201154465103022017Copyright ©; 2011, Pchelina S.N.Copyright ©; 2011, Pchelina S.N.2011Pchelina S.N.Pchelina S.N.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/289

Parkinson’s disease (PD) is a common neurodegenerative disorder. Toxic aggregation of a small presynaptic protein alpha-synuclein is considered to be the main step in the pathogenesis of PD. Today there are no suitable diagnostic tests based on biochemical investigation of such readily accessible tissues as blood and cerebrospinal fluid (CSF). A search for PD biomarkers aimed at diagnosis and monitoring of the disease remains very actual. As suggested in several studies, the use of the peripheral alphasynuclein level might be a prognostic marker for PD, but until now this question remains open. Evaluation of blood and CSF alpha-synuclein levels in patients with PD compared with agematched controls provided conflicting results. Specific detection and quantification of oligomeric forms of alpha-synuclein in combination with the improvement of imaging techniques may be considered as most perspective direction.

В качестве основного звена патогенеза болезни Паркинсона (БП) рассматривается формирование нейротоксических агрегатов небольшого пресинаптического белка альфа-синуклеина. Сегодня не существует диагностических тестов БП, основанных на биохимических исследованиях доступных биологических жидкостей (кровь, цереброспинальная жидкость). Поиск биомаркеров, позволяющих проводить диагностику и мониторинг заболевания, остается крайне актуальным. В ряде исследований предложено использование уровня периферического альфа-синуклеина в качестве прогностического маркера БП, однако до настоящего момента этот вопрос остается открытым. Работы по сопоставлению уровня мономерного альфа-синуклеина лимфоцитов периферической крови, плазмы и цереброспинальной жидкости у пациентов с БП и в контроле носят противоречивый характер. Разработка методов выявления и количественной оценки олигомерных форм альфа-синуклеина в сочетании с развитием методов нейровизуализации может рассматриваться как наиболее перспективное направление.

Parkinson’s diseasebiomarkersalpha-synucleinболезнь Паркинсонабиомаркерыальфа-синуклеинИллариошкин С.Н. Конформационные болезни мозга. М.: Янус-К, 2003.Иллариошкин С.Н., Иванова-Смоленская И.А., Маркова Е.Д. ДНК-диагностика и медико-генетическое консультирование в неврологии. М.: МИА, 2002.Литвиненко И.В., Одинак М.М., Сологуб О.С. и др. Гипергомоцистеинемия при болезни Паркинсона – новый вариант осложнений проводимой терапии или специфический биохимический маркер заболевания? Анн. клин. эксп. неврол. 2008; 2: 13–17.Пчелина С.Н., Емельянов А.К., Якимовский А.Ф. и др. Сниженный уровень альфа-синуклеина в лейкоцитах периферической крови у пациентов с LRRK2-ассоциированной болезнью Паркинсона. Бюл. эксп. биол. мед. 2010; 12: 619–621.Пчелина С.Н., Иванова О.Н., Емельянов А.К. и др. Мутации в гене LRRK2 у больных с болезнью Паркинсона в России. Мед. ген. 2006; 5: 48–51.Пчелина С.Н., Якимовский А.Ф., Шварц Е.И. Наследственные основы болезни Паркинсона. Мед. ген. 2003; 9: 411–425.Скоромец А.А., Скоромец А.П., Скоромец Т.А. Нервные болезни. М.: МЕДпресс-информ, 2005.Угрюмов М.В. (ред.) Нейродегенеративные заболевания. Фундаментальные и прикладные аспекты. М.: Наука, 2010.Aerts M.B., Esselink R.A., Abdo W.F. et al. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 2011 (e-pub ahead of print).Anderson J., Walker D.E., Goldstein J.M. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006; 281: 29739–29752.Barbour R., Kling K., Anderson J.P. et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegen. Dis. 2008; 5: 55-59.Bisaglia M., Greggio E., Dragan M. et al. α-Synuclein overexpression increases dopamine toxicity in BE(2)-M17. Cells BMC Neuroscience 2010; 11: 41.Bisaglia M., Mammi S., Bubacco L. Structural insights on physiological functions and pathological effects of alpha-synuclein. FASEB J. 2009; 23: 329–340.Brighina L., Prigione A., Begni B. et al. Lymphomonocyte alphasynuclein levels in aging and in Parkinson disease. Neurobiol. Aging 2010; 31: 884–885.Cabin D.E., Shimazu K., Murphy D. et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002; 22: 8797–8807.Carballo-Carbajal I., Weber-Endress S., Rovelli G. et al. Leucinerich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal. 2010; 22: 821–827.Carotini B., Tanda G., Colosimo C. Reduced dopamine in peripheral blood lymphocytes in Parkinson’s disease. NeuroReport 1999; 10: 2907–2920.Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998; 4: 1318–1320.Cookson M.R., van der Brug M. Cell systems and the toxic mechanism( s) of alpha-synuclein. Exp Neurol. 2008; 209: 5–11.Davidson W.S., Jonas A.., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998; 273: 9443–9449.El-Agnaf O.M., Salem S.A., Paleologou K.E. et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 2006; 20: 419–425.Feany M.B., Bender W.W. A drosophila model of Parkinson’s disease. Nature 2000; 404: 394–398.Fuchs J., Tichopad A., Golub Y. et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008; 22: 1327–1334.Giasson B.I., Murray I.V., Trojanowski J.Q., Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 2001; 276: 2380–2386.Greggio E., Bisaglia M., Civiero L., Bubacco L. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson’s disease? Mol. Neurodegen. 2011; 6: 6.Greten-Harrison B., Polydoro M., Morimoto-Tomita M. et al. αβγ- Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. PNAS 2010; 107: 19573–19578.Hong Z., Shi M., Chung K.A. et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010; 133: 713–726.Ibáñez P., Lesage S., Janin S. et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch. Neurol. 2009; 66: 102–108.Kikuchi A., Takeda A., Okamura N. et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol- 5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010; 133: 1772–1778.Kim S., Seo J.H., Suh Y.H. Alha-synuclein, Parkinson’s disease, and Alzheimer’s disease. Parkinsonism. Relat. Disord. 2004; 10: S9–13.Kruger R., Kuhn W., Muller T. et al. Ala30Pro mutation in the gene encoding alphasynuclein in Parkinson’s disease. Nat. Genet. 1998; 18: 106–108Lee F.J.S., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J. 2001; 15: 916–926.Lee P.H., Lee G., Park H.J. et al. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J. Neural Transm. 2006; 13: 1435–1439.Li Q.X., Mok S.S., Laughton K.M. et al. Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease. Exp. Neurol. 2007; 204: 583–588.Luk K.C., Song C., O’Brien P. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. PNAS 2009; 106: 20051–20056.Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein — a neuron- specific protein localized to the nucleus and presynaptic nerve-terminal. J. Neurosci. 1988; 8: 2804–2815.Masliah E., Rockenstein E., Veinbergs I. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265–1269.Michell A.W., Luheshi L.M., Barker R.A. Skin and platelet alphasynuclein as peripheral biomarkers of Parkinson’s disease. Neurosci. Lett. 2005; 381: 294–298.Miller D.W., Crawley A., Gwinn-Hardy K. et al. Unaltered alphasynuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. Neurosci. Lett. 2005; 374: 189–191.Miller D.W., Hague S.M., Clarimon J. et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004; 62: 1835–1838.Mollenhauer B., Cullen V., Kahn I. et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 2008; 213: 315–325.Nemani V.M., Lu W., Berge V. et al. Increased expression of alphasynuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010; 65: 66–79.Nishioka K., Hayashi S., Farrer M.J. et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann. Neurol. 2006; 59: 298–309.Pankratz N., Nichols W.C., Elsaesser V.E. et al. Alpha-synuclein and familial Parkinson’s disease. Mov. Disord. 2009; 24: 1123–1125.Pchelina S.N., Yakimovskii A.F., Emelyanov A.K. et al. Screening for LRRK2 mutations in patients with Parkinson’s disease in Russia: identification of a novel LRRK2 variant. Eur. J. Neurol. 2008; 15: 692–696.Pchelina S.N., Yakimovskii A.F., Ivanova O.N. et al. G2019S LRRK2 mutation in familial and sporadic Parkinson’s disease in Russia. Mov Disord. 2006; 21: 2234–2236.Pellicano C., Buttarelli F.R., Circella A. et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor. J. Neural Transm. 2007; 114: 935–938.Perez R., Waymire J.C., Lin E. et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002; 22: 3090–3099.Polwey E.D., Cherra S.J., Liu Y., Chu C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortenibg in differentiated SHSY5Y cells. J. Neurocem. 2008; 105: 1048–1056.Polymeropoulos M.H., Lavedan C., Leroy E. et al. Mutation in the alpha-synuclein gene identifi ed in families with Parkinson’s disease. Science 1997; 276: 2045–2047.Prigione A., Piazza F., Brighina L. et al. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease. Neurosci. Lett. 2010; 477: 6–10.Qing H., Wong W., McGeer E.G. et al. Lrrk2 phosphorylates alphasynuclein at serine 129: Parkinson disease implications. BBRC 2009; 387: 149–152.Satake W., Nakabayashi Y., Mizuta I. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat. Genet. 2009; 41: 1303–1307.Shi M., Bradner J., Hancock A.M. et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011; 69: 570–580.Simón-Sánchez J., Schulte C., Bras J.M. et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 2009; 41: 1308–1312.Singleton A.B., Farrer M., Johnson J. et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science 2003; 302(5646): 841.Spillantini M.G., Schmidt M.L., Lee V.M.Y. et al. Alph-asynuclein in Lewy bodies. Nature 1997; 388: 839–840.Tokuda T., Qureshi M.M., Ardah M.T. et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 75: 1766–1772.Ueda K., Fukushima H., Masliah E. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. PNAS 1993; 90: 11282–11286.Vernon A.C., Ballard C., Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? Brain Res. Rev. 2010; 65: 28–55.Waxman E.A., Giasson B.I. A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J. Neurochem. 2010; 113: 374–88.Westerlund M., Belin A.C., Anvret A. et al. Cerebellar alpha-synuclein levels are decreased in Parkinson’s disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J. 2008; 22: 3509–3514.Zarranz J.J., Alegre J., Gomez-Esteban J.C. et al. The new mutation, E46K, of alpha- synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004; 55: 164–173.